How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,476 results for

Tocolytic

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Magnesium and Vascular Stiffness

of Drugs Anesthetics Central Nervous System Depressants Anti-Arrhythmia Agents Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Calcium-Regulating Hormones and Agents Tocolytic Agents Reproductive Control Agents Cathartics Gastrointestinal Agents Antacids

2018 Clinical Trials

182. Verify the Safety and Effectiveness of the Cerclage Pessary in Prevention and Treatment of High-risk Preterm Pregnancy

of chorioamnionitis Hospitalisation for threatened preterm labour before 32 weeks(Case Report Form) [ Time Frame: before 37+0 weeks ] requirement of hospitalisation due to preterm contractions that need medical treatment to try to stop them before 31+6 weeks Mean hospital stay duration: number of days of admittance at the hospital Use of tocolytic treatment: Type of tocolytic, days of treatment, dose Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study

2018 Clinical Trials

183. Deleterious genetic variants in ciliopathy genes increase risk of ritodrine-induced cardiac and pulmonary side effects Full Text available with Trip Pro

Deleterious genetic variants in ciliopathy genes increase risk of ritodrine-induced cardiac and pulmonary side effects Ritodrine is a commonly used tocolytic to prevent preterm labour. However, it can cause unexpected serious adverse reactions, such as pulmonary oedema, pulmonary congestion, and tachycardia. It is unknown whether such adverse reactions are associated with pharmacogenomic variants in patients.Whole-exome sequencing of 13 subjects with serious ritodrine-induced cardiac

2018 BMC medical genomics

184. Delayed interval delivery of the second twin in a woman with altered markers of inflammation. Full Text available with Trip Pro

Delayed interval delivery of the second twin in a woman with altered markers of inflammation. Delayed interval intertwin delivery rates are expected to rise during the next years as potent and targeted tocolytic agents are employed and antenatal surveillance methods become more sophisticated and specific in predicting the critical delivery timepoint of optimal perinatal outcome.We present a case of delayed intertwin delivery after delivery of the first twin due to premature prelabor rupture

2018 BMC Pregnancy and Childbirth

185. Magnesium for Shivering in Epidural Lidocaine Deliveries

-Regulating Hormones and Agents Tocolytic Agents Reproductive Control Agents

2018 Clinical Trials

187. Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome

: enrollment till birth, maximum 21 weeks ] recording of days of hospitalisation for threatened preterm labour before 31 +6 weeks of gestation and recording tocolytic treatment (type/ days/dose) premature rupture of membranes (ProM) before 31 +6 weeks of gestation [ Time Frame: enrollment till birth, maximum 21 weeks ] rate of women with premature rupture of membranes (ProM) before 31 +6 weeks of gestation Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate

2018 Clinical Trials

188. Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB

of cervical pessary at enrollment till removal of cervical pessary at WoG 37, maximum 25 weeks ] rate of maternal physical or psychological intolerance to pessary during pregnancy Hospitalisation for threatened preterm labour before 31+6 weeks [ Time Frame: randomization till birth, maximum 20 weeks ] Hospitalisation for threatened preterm labour before 31+6 weeks: recording of days of hospitalisation and tocolytic treatment: type / days / dose premature rupture of membranes (PRoM) before 31+6 weeks

2018 Clinical Trials

189. Early Versus Traditional Oral Hydration After Cesarean Section

Such as intestinal injury. Medical disorders such as Diabetes and Hypertension Factors that may influence postpartum blood loss as anemia, multiple pregnancy and polyhydraminos. Use of tocolytic drugs Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03442634

2018 Clinical Trials

190. Interest of a Vaginal Swab in Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth

, as well as a decrease of treatments pointlessly prescribed at the patients not giving birth finally prematurely (tocolytics, corticoids). For those giving birth prematurely, corticoids could be administered for an optimal deadline to obtain the maximal profit for the newborn child. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 400 participants Observational Model: Case-Only Time Perspective: Prospective Official Title: Prospective Multicentric (...) with a positive test who did not give birth within 7 days Gestational age less than 34 weeks and 37 weeks at the time of birth. hospital stays [ Time Frame: time to delivery ] Economic impact evaluation PAMG-1 tests consumption [ Time Frame: time to delivery ] Economic impact evaluation corticosteroid treatments consumption [ Time Frame: time to delivery ] Economic impact evaluation tocolytic treatments consumption [ Time Frame: time to delivery ] Economic impact evaluation Biospecimen Retention: Samples

2018 Clinical Trials

191. Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers

Tissue Diseases Skin Diseases Nifedipine Iloprost Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Vasodilator Agents Tocolytic Agents Reproductive Control Agents Platelet Aggregation Inhibitors

2018 Clinical Trials

192. Effects of Noninvasive Ventilation Compared to Salbutamol

Respiratory System Agents Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action

2018 Clinical Trials

193. A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action

2018 Clinical Trials

194. A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.

Hormones, Hormone Substitutes, and Hormone Antagonists Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action

2018 Clinical Trials

195. S-Nitrosoglutathione Reductase Underlies the Dysfunctional Relaxation to Nitric Oxide in Preterm Labor Full Text available with Trip Pro

S-Nitrosoglutathione Reductase Underlies the Dysfunctional Relaxation to Nitric Oxide in Preterm Labor Tocolytics show limited efficacy to prevent preterm delivery. In uterine smooth muscle cGMP accumulation following addition of nitric oxide (NO) has little effect on relaxation suggesting a role for protein S-nitrosation. In human myometrial tissues from women in labor at term (TL), or spontaneously in labor preterm (sPTL), direct stimulation of soluble guanylyl cyclase (sGC) fails to relax (...) contraction can reveal new tocolytic targets.

2018 Scientific reports

196. Functional comparison of anoctamin 1 antagonists on human uterine smooth muscle contractility and excitability Full Text available with Trip Pro

Functional comparison of anoctamin 1 antagonists on human uterine smooth muscle contractility and excitability Pre-term birth is a major health care challenge throughout the world, and preterm labor represents a potentially reversible component of this problem. Current tocolytics do not improve preterm labor beyond 48 h. We have previously shown that anoctamin 1 (ANO1) channel blockade results in relaxation of pre-contracted human uterine smooth muscle (USM). Three drug classes with reported (...) -induced calcium flux (in vitro human USM cells) and 3) Membrane potential assay (in vitro human USM cells).Benzbromarone (BB) demonstrated the greatest potency among the compounds tested with respect to force, frequency inhibition, reducing calcium elevation and depolarizing membrane potential.While all 3 ANO1 antagonists attenuate pregnant human uterine tissue contractility and excitability, BB is the most potent tocolytic drug. Our findings may serve as a foundation for future structure-function

2018 Journal of Smooth Muscle Research

197. Systematic review: Calcium channel blockers are effective as first line for tocolysis in the management of preterm labour Full Text available with Trip Pro

blockers are effective as first line for tocolysis in the management of preterm labour Richard G Brown , David A MacIntyre Statistics from Altmetric.com Commentary on : Flenady V , Wojcieszek AM , Papatsonis DN , et al . Calcium channel blockers for inhibiting preterm birth . Context Preterm birth remains as the leading cause of neonatal morbidity and mortality. Although tocolytics do not reduce the risk of preterm birth, they effectively delay delivery by 48 h. 1 This creates a window of opportunity (...) for corticosteroid administration and transfer to units with neonatal intensive care unit (NICU) facilities, which improves neonatal mortality and morbidity. 2 However, a consensus on the most effective tocolytic does not exist. This study aimed to assess the effects of calcium channel blockers (CCBs) on maternal, fetal and neonatal outcomes when administered to women in preterm labour. Methods This was an updated review of randomised trials using CCBs as tocolytics for management of preterm birth. Maternal

2014 Evidence-Based Medicine

198. Safe Prevention of the Primary Cesarean Delivery

bolus ( ), and tocolytic agents ( ) are routine components of intrauterine resuscitation ( ) that have extremely limited data for effectiveness or safety. Performance of these interventions without a subsequent change in fetal heart rate pattern is not necessarily an indication for cesarean delivery. Medication exposure, regional analgesia, rapid labor progress, cervical examination, infection, maternal hypotension, and maternal fever all can affect the fetal heart rate pattern (48). Attention

2014 American College of Obstetricians and Gynecologists

199. ASPEN Clinical Guidelines: Nutrition Support of Neonatal Patients at Risk for Metabolic Bone Disease

skeleton and neonatal bone health. 6 Our literature review identified a few salient maternal nutrition factors that have been studied in relation to neonatal bone health, including maternal vitamin D deficiency, the administration of intravenous (IV) magne- sium sulfate as a tocolytic agent, and maternal folic acid intake.572 Journal of Parenteral and Enteral Nutrition 37(5) Several studies have attempted to correlate maternal vita- min D status with neonatal bone health. Five observational studies met (...) and neonatal health. Given the paucity of data and the poor quality of the available data, 30,31 it is difficult to determine whether the prolonged administration of magnesium sulfate as a tocolytic agent has a detrimental effect on neonatal bone health, and thus, future prospective studies are necessary before any defin- itive recommendation can be made. Folic acid is known to play an important role in normal growth and likely also plays a role in normal bone formation and growth. Furthermore, data exist

2013 American Society for Parenteral and Enteral Nutrition

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>